These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26329166)

  • 1. Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells.
    Ma G; Pan Y; Zhou C; Sun R; Bai J; Liu P; Ren Y; He J
    Oncol Rep; 2015 Nov; 34(5):2423-30. PubMed ID: 26329166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.
    Haagenson KK; Zhang JW; Xu Z; Shekhar MP; Wu GS
    Oncotarget; 2014 Feb; 5(4):1101-10. PubMed ID: 24658355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
    Tomlinson DC; Knowles MA; Speirs V
    Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
    Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
    Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
    Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
    Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
    Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
    Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
    Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
    Mandlekar S; Yu R; Tan TH; Kong AN
    Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.
    Candas D; Lu CL; Fan M; Chuang FY; Sweeney C; Borowsky AD; Li JJ
    Cancer Res; 2014 Dec; 74(24):7498-509. PubMed ID: 25377473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p.
    Liu Y; Li M; Yu H; Piao H
    Int J Mol Med; 2020 Feb; 45(2):497-509. PubMed ID: 31894257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine enhances the anti‑tumor activity of tamoxifen in drug‑sensitive MCF‑7 and drug‑resistant MCF‑7/TAM cells.
    Wen C; Wu L; Fu L; Zhang X; Zhou H
    Mol Med Rep; 2016 Sep; 14(3):2250-6. PubMed ID: 27432642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition.
    Wang Q; Shi S; He W; Padilla MT; Zhang L; Wang X; Zhang B; Lin Y
    Oncotarget; 2014 Mar; 5(5):1304-14. PubMed ID: 24675421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.